Aldesleukin Intravenous and Gonadotropin, Chorionic

• Generic Name: aldesleukin
• Dosage Forms: n.a.
• Other Brand Names: Proleukin

Aldesleukin injection is anticancer medicine that is used to treat metastatic kidney cancer (cancer that has already spread to the body) and metastatic skin cancer.

Aldesleukin is a man-made version of a substance called interleukin-2. Interleukins are produced naturally by cells in the body to help white blood cells work.

Aldesleukin causes very serious side effects in addition to its helpful effects. Some effects can be fatal. For that reason, aldesleukin injection is given only in the hospital. If severe side effects occur, which is common, treatment in an intensive care unit (ICU) may be necessary. Other effects may not be serious but may cause concern. Before you begin treatment with aldesleukin, you and your doctor should talk about the benefits aldesleukin will do as well as the risks of using it.

Aldesleukin is to be administered only by or under the immediate supervision of your doctor.

• Generic Name: chorionic gonadotropin (hcg)
• Dosage Forms: n.a.
• Other Brand Names: Novarel, Ovidrel, Pregnyl, APL, Profasi, Chorex, Gonic, Hcg, Chorigon, Choron-10

Management of prepubertal cryptorchidism not caused by anatomical obstruction.

Induction of testicular descent usually only temporary; response may be permanent in some patients.

Differential diagnosis (hCG stimulatory test) of cryptorchidism in prepubertal boys to predict whether subsequent orchidopexy will be required. In general, hCG is thought to induce testicular descent in patients in whom descent would have occurred at puberty.

Start corrective therapy for cryptorchidism before pubescence to prevent irreparable testicular damage; opinions differ regarding optimum age for treatment. Manufacturers recommend instituting u-hCG therapy for prepubertal cryptorchidism in boys 4–9 years of age.

Management of hypogonadotropic hypogonadism resulting from pituitary deficiency.

Stimulation of spermatogenesis in males with hypogonadotropic hypogonadism secondary to pituitary deficiency. Full response may require concurrent FSH or menotropins therapy.

Used in conjunction with follicle-stimulating agent(s) (e.g., menotropins as fixed-combination preparations or separate components, FSH) to induce ovulation in anovulatory, infertile women in whom anovulation is secondary (e.g., pituitary insufficiency).

Should not be used in infertile women in whom anovulation is due to primary ovarian failure.

Has been used for the treatment of infertility resulting from deficiency of corpus luteum during luteal phase of menstrual cycle.

Manufacturer states that u-hCG has not been shown to be effective as adjunctive therapy for the treatment of obesity.